1. Home
  2. NOAH vs MYGN Comparison

NOAH vs MYGN Comparison

Compare NOAH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOAH
  • MYGN
  • Stock Information
  • Founded
  • NOAH 2005
  • MYGN 1991
  • Country
  • NOAH China
  • MYGN United States
  • Employees
  • NOAH N/A
  • MYGN N/A
  • Industry
  • NOAH Investment Managers
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • NOAH Finance
  • MYGN Health Care
  • Exchange
  • NOAH Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • NOAH 767.0M
  • MYGN 642.0M
  • IPO Year
  • NOAH 2010
  • MYGN 1995
  • Fundamental
  • Price
  • NOAH $11.86
  • MYGN $7.58
  • Analyst Decision
  • NOAH Buy
  • MYGN Hold
  • Analyst Count
  • NOAH 2
  • MYGN 13
  • Target Price
  • NOAH $12.25
  • MYGN $13.50
  • AVG Volume (30 Days)
  • NOAH 212.3K
  • MYGN 1.5M
  • Earning Date
  • NOAH 11-25-2025
  • MYGN 11-06-2025
  • Dividend Yield
  • NOAH 4.91%
  • MYGN N/A
  • EPS Growth
  • NOAH N/A
  • MYGN N/A
  • EPS
  • NOAH 0.75
  • MYGN N/A
  • Revenue
  • NOAH $360,100,505.00
  • MYGN $832,900,000.00
  • Revenue This Year
  • NOAH N/A
  • MYGN $0.17
  • Revenue Next Year
  • NOAH $5.17
  • MYGN $6.19
  • P/E Ratio
  • NOAH $16.01
  • MYGN N/A
  • Revenue Growth
  • NOAH N/A
  • MYGN 3.83
  • 52 Week Low
  • NOAH $7.67
  • MYGN $3.76
  • 52 Week High
  • NOAH $14.90
  • MYGN $26.60
  • Technical
  • Relative Strength Index (RSI)
  • NOAH 51.24
  • MYGN 55.60
  • Support Level
  • NOAH $11.01
  • MYGN $7.04
  • Resistance Level
  • NOAH $12.43
  • MYGN $8.25
  • Average True Range (ATR)
  • NOAH 0.39
  • MYGN 0.38
  • MACD
  • NOAH 0.08
  • MYGN -0.05
  • Stochastic Oscillator
  • NOAH 61.05
  • MYGN 45.74

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: